%20IF%20Banner%202025.svg)
(Toronto, ON, June 19, 2025) JMIR Publications is pleased to announce that JMIR Cancer has received a Journal Impact Factor of 2.7, as published in Journal Citation Reports 2025 from Clarivate.
This achievement highlights the importance of research on patient-centered innovations, education, and technology for cancer care, cancer survivorship, and cancer research.
This year’s Journal Impact Factor (2024 data) for JMIR Cancer reflects the high-quality and impactful research contributed by the published authors, the rigorous work of peer reviewers, and the dedication of editors and journal staff. JMIR Cancer also recently received a 2024 CiteScore of 5.9, ranking in Q2 in the Oncology category—the journal's top-ranked category. CiteScore is a 4-year average of citations, based on Elsevier Scopus data.
This success builds upon JMIR Publications’ overall strong performance in the Journal Citation Reports 2025 from Clarivate and complements the journal’s recent achievements in the Scopus CiteScore rankings.
To view a full list of JMIR Publications journals with a Journal Impact Factor, please visit the website.
JMIR Publications recommends that authors and other parties consider alternative metrics, in combination with the Journal Impact Factor, when assessing a journal’s standing and impact. While proud of its Journal Impact Factor rankings, JMIR Publications discourages misuse of citation-based impact scores.
Source: Journal Citation Reports 2025 from Clarivate